P
Prevail Therapeutics
A biotechnology company
About Prevail Therapeutics
Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company, operates as a biotechnology firm with a sharp focus on developing and commercializing AAV9-based gene therapies for patients with neurodegenerative diseases. The company was established in 2017 by Dr. Asa Abeliovich, who brought his extensive background in neuroscience and genetics from his time as a tenured professor at Columbia University, to address the genetic underpinnings of these debilitating conditions. Dr. Abeliovich's academic research, particularly in molecular mechanisms of neurodegenerative disorders like Parkinson’s disease and dementia, formed the scientific bedrock of Prevail's therapeutic approach.
Read full description
The company's strategic direction was significantly shaped by its acquisition by Eli Lilly and Company in January 2021 for an aggregate value of approximately $1.04 billion. This milestone provided Prevail with substantial resources to advance its clinical programs while allowing it to maintain its entrepreneurial and research-focused culture. Prevail's pipeline is centered on one-time gene therapies designed to slow or stop the progression of diseases by correcting the root genetic cause. Its portfolio includes investigational treatments for genetically defined forms of Parkinson's disease (GBA1), frontotemporal dementia (GRN), and other central nervous system disorders.
The business model is typical of a clinical-stage biotechnology company, where value is created through the research and development of drug candidates, navigating them through the rigorous phases of clinical trials, and ultimately seeking regulatory approval for commercialization. Prevail's target market consists of patient populations with specific genetic mutations that lead to neurodegenerative conditions, a segment with high unmet medical needs. The therapies are designed to be administered a single time, aiming to provide a long-term, durable effect, which constitutes their primary therapeutic and commercial proposition.
At a glance
- Founded
- 2017
- Headquarters
- New York City, United States
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Prevail Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
OrbiMed
Alexandria Venture Investments
EcoR1 Capital
Abbvie Biotech Ventures
Omega Funds
RA Capital Management
Boxer Capital
Series B and later6 investors entered at this stage
- AIAlexandria Venture Investments
- AVAbbvie Biotech Ventures
- RA Capital Management
- OFOmega Funds
- ECEcoR1 Capital
- BCBoxer Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
19 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Prevail Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Prevail Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.